TNFRSF17 and Miyoshi myopathy: Recently, there has been a wide availability of different drugs and classes against BCMA: antibody–drug conjugates (ADC), bispecific antibodies (BsAb), chimeric antigen receptor T-cells (CAR-T) products, mainly used in randomized trials and also in clinical practice in advanced stages of MM, following the most common drugs, such as proteasome inhibitors (PI), immunomodulatory drugs (IMiD), anti-CD38 and anti-signaling lymphocyte activation molecule F7 (SLAMF7) monoclonal antibodies (mAb).